MedTrace Logo

A RESearch on the PrEvalence and the Diagnosis of COPD and Its Tobacco-related Etiology

NCT02307799 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3133

Last updated 2019-01-23

No results posted yet for this study

Summary

The aim of the RESPECT study is to gain a better understanding of the prevalence, pathogenesis and symptoms of early chronic obstructive pulmonary disease (COPD). This study seeks to address the following specific objectives/research questions: 1) to estimate the prevalence of airflow limitation (AL) and COPD in adults 35-70 years of age in St.Petersburg and Arkhangelsk based on sex, age, environmental conditions, socioeconomic status and smoking status; 2) to compare the prevalence of COPD in the study population based on the Global Strategy for Diagnosis, Management and Prevention of COPD (GOLD) and lower limit of normal (LLN) criteria; 3) to identify the diagnostic value of various signs, symptoms and background characteristics for the diagnosis of COPD; 4) to determine whether differences in background characteristics and inflammatory biomarkers are evident between smokers with and without COPD; and 5) to describe co-morbidity, functionality and global health status in a cohort of newly diagnosed COPD patients.

Conditions

Sponsors & Collaborators

  • Northern State Medical University

    collaborator OTHER

  • Université Catholique de Louvain

    lead OTHER

Principal Investigators

  • Jean-Marie Degryse, professor · Université Catholique de Louvain, Brussels, Belgium

  • Olga Yu Kuznetsova, professor · North-West State Medical University, St Petersburg, Russia

  • Elena A Andreeva, PhD · Northern State Medical University, Arkhangelsk, Russia

  • Marina A Pokhaznikova, PhD · North-West State Medical University, St Petersburg, Russia

Eligibility

Min Age
35 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2018-01-31
Completion
2019-01-31

Countries

  • Russia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02307799 on ClinicalTrials.gov